Search results for "Co-occurring genomic alterations"

showing 1 items of 1 documents

Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor sampl…

2019

[Background] Approximately 30% of tumor biopsies from patients with advanced-stage lung adenocarcinomas yield insufficient tissue for successful molecular subtyping. We have analyzed the clinical utility of next-generation sequencing (NGS) of cell-free circulating tumor DNA (ctDNA) in patients with inadequate tumor samples for tissue genotyping. [Patients and methods] We conducted the study in a multi-institutional prospective cohort of clinically unselected patients with advanced-stage lung adenocarcinomas with insufficient tissue for EGFR, ALK or ROS1 genotyping across 12 Spanish institutions (n = 93). ctDNA NGS was carried out by Guardant Health (Guardant360, Redwood City, CA), using a h…

MaleLung adenocarcinoma0301 basic medicineOncologyLung NeoplasmsCirculating Tumor DNA0302 clinical medicineco-occurring genomic alterationsGenotypeProspective StudiesNeoplasm MetastasisPrecision MedicineStage (cooking)Prospective cohort studyInsufficient tissueAged 80 and overactionable genomic alterationsHazard ratioHigh-Throughput Nucleotide SequencingDNA NeoplasmGenomicsinsufficient tissueHematologyMiddle AgedActionable genomic alterationsPrognosisSurvival Ratemedicine.anatomical_structureOncology030220 oncology & carcinogenesisFemaleAdultmedicine.medical_specialtydigital next-generation sequencingAdenocarcinoma of Lung03 medical and health sciencesProto-Oncogene ProteinsInternal medicineBiomarkers TumormedicineROS1HumansLung cancerGenotypingAgedDigital next-generation sequencingLungGenome Humanbusiness.industryctDNACo-occurring genomic alterationslung adenocarcinomamedicine.disease030104 developmental biologyMutationbusinessFollow-Up StudiesAnnals of Oncology
researchProduct